아시아태평양의 당뇨병성 족부 궤양 시장 전망(-2030년) : 지역별 분석 - 궤양 유형, 치료 유형, 감염 중증도, 최종 사용자별

Asia Pacific Diabetic Foot Ulcer Market Forecast to 2030 - Regional Analysis -By Ulcer Type, Treatment Type, Infection Severity, and End User

US $ 3,450 ￦ 4,991,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450 ￦ 6,438,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450 ￦ 7,885,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아시아태평양의 당뇨병성 족부 궤양 시장은 2022년 14억 5,582만 달러로 평가되었습니다. 2030년에는 24억 7,261만 달러에 달할 것으로 예상되며, 2022-2030년간 연평균 6.8%의 성장률을 나타낼 전망입니다.

노령인구의 급격한 증가로 아시아태평양의 당뇨병성 족부 궤양 시장이 활성화되고 있습니다.

노화에 따른 당뇨병은 전 세계적으로 흔한 질병입니다. 인슐린 분비 부족은 나이가 들어감에 따라 체성분 변화와 근육 감소로 인해 인슐린 저항성이 증가합니다. 내분비학회에 따르면 65세 이상 성인의 약 33%가 당뇨병을 앓고 있다고 합니다. 또한, Global Ageing Survey 2019에 따르면 2050년까지 전 세계 대부분의 지역에서 고령화 속도(60세 이상 고령자)가 거의 4분의 1 이상으로 증가할 것으로 예상됩니다. 노인들은 당뇨병에 걸릴 확률이 높고, 삶의 질에 심각한 영향을 미치는 당뇨병성 족부 궤양과 만성 상처가 발생할 가능성이 높을 것으로 예상됩니다. 따라서 고령화 인구가 증가함에 따라 고급 당뇨병성 족부 궤양 치료제에 대한 수요는 향후 몇 년동안 계속 증가할 것으로 예상됩니다.

아시아태평양의 당뇨병성 족부 궤양 시장 개요

당뇨병성 족부 궤양은 아시아태평양 인구의 주요 절단 원인 중 하나입니다. Diabetic Feet Australia에 따르면, 2023년까지 약 30만 명의 호주인이 당뇨병성 족부 질환에 걸릴 위험이 있으며, 5만 명이 당뇨병성 족부 질환을 앓고 있는 것으로 추산됩니다. 당뇨병성 족부 질환을 앓고 있는 것으로 추정됩니다. 마찬가지로 2023년 Wiley Online Library에 게재된 연구에 따르면 중국의 당뇨병성 족부 질환은 당뇨병 인구의 30%에 달할 전망입니다. 따라서 이 지역의 당뇨병성 족부 질환의 유병률은 향후 몇 년동안 시장 성장을 가속할 것으로 보입니다.

아시아태평양 시장 개척 기업들은 당뇨병성 족부 궤양 치료법을 적극적으로 개발하고 있습니다. 예를 들어, 호주에 본사를 둔 생명공학 기업 Cannenta는 당뇨병성 족궤양에 대한 첨단 상처 치료법을 개발하고 있으며, 2021년 3월에는 호주의 임상 단계에 있는 줄기세포 및 재생의료 기업 Sinata Therapeutics가 Sinata의 와 당뇨병성 족궤양용 간엽줄기세포 제품의 상업적 개발을 위해 파트너십을 체결했습니다. 따라서 당뇨병 유병률 증가, 당뇨병성 족부질환 환자 증가, 시장 진출기업들의 노력이 아시아태평양 시장 성장을 견인할 것으로 예상됩니다.

아시아태평양의 당뇨병성 족부 궤양 시장 매출 및 2030년까지 예측(금액)

아시아태평양의 당뇨병성 족부 궤양 시장 세분화

치료 유형별로 보면, 아시아태평양의 당뇨병성 족부 궤양 시장은 고급 상처 치료 드레싱, 치료 장치, 생물학적 제제로 구분되며, 2022년에는 고급 상처 치료 드레싱 재료 부문이 더 큰 점유율을 차지할 것으로 예상됩니다.

궤양의 유형에 따라 아시아태평양의 당뇨병성 족부 궤양 시장은 신경허혈성 궤양, 신경병성 궤양, 허혈성 궤양으로 구분되며, 2022년에는 신경허혈성 궤양 부문의 점유율이 더 커질 것으로 예상됩니다.

감염의 중증도에 따라 아시아태평양의 당뇨병성 족부 궤양 시장은 경증, 중등도, 중증으로 구분되며, 2022년에는 경증 부문이 더 큰 점유율을 차지할 것으로 예상됩니다.

최종 사용자별로 아시아태평양의 당뇨병성 족부 궤양 시장은 병원, 외래수술센터(ASC), 재택치료로 구분되며, 2022년에는 병원 부문이 더 큰 점유율을 차지할 것으로 예상됩니다.

국가별로 아시아태평양의 당뇨병성 족부 궤양 시장은 중국, 한국, 일본, 호주, 인도, 기타 아시아태평양으로 구분됩니다. 중국이 2022년 아시아태평양 당뇨병성 족부 궤양 시장을 장악했습니다.

Convatec Group Plc, 3M Co, Coloplast AS, Smith &Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc, Molnlycke Health Care AB, MiMedx Group Inc, URGO Medical Australia Pty Ltd는 아시아태평양의 당뇨병성 족부 궤양 시장에서 활동하는 주요 기업 중 일부입니다.

목차

목차

제1장 서론

제2장 주요 요약

• 주요 인사이트

제3장 조사 방법

• 조사 범위
• 2차 조사
• 1차 조사

제4장 아시아태평양의 당뇨병성 족궤양 시장 구도

제5장 아시아태평양의 당뇨병성 족궤양 시장 : 주요 산업 역학

• 시장 성장 촉진요인
• 주요 시장 성장 억제요인
• 주요 시장 기회
• 향후 동향
• 영향 분석

제6장 당뇨병성 족궤양 시장 : 아시아태평양 시장 분석

• 아시아태평양의 당뇨병성 족궤양 시장 매출, 2022년-2030년

제7장 아시아태평양의 당뇨병성 족궤양 시장 - 매출과 예측(-2030년) : 치료 유형별

• 시장 매출 점유율, 2022년 및 2030년
• 첨단 창상관리 드레싱
• 생물제제
• 치료기기

제8장 아시아태평양의 당뇨병성 족궤양 시장 - 매출과 예측(-2030년) : 궤양 유형별

• 시장 매출 점유율, 2022년 및 2030년
• 신경장애성 궤양
• 허혈성 궤양
• 신경허혈성 궤양

제9장 아시아태평양의 당뇨병성 족궤양 시장 - 매출과 예측(-2030년) : 감염 중증도별

• 시장 매출 점유율, 2022년 및 2030년
• 경증, 중등증, 중증

제10장 아시아태평양의 당뇨병성 족궤양 시장 - 매출과 예측(-2030년) : 최종사용자별

• 시장 매출 점유율, 2022년 및 2030년
• 병원
• 외래수술센터(ASC)
• 재택치료

제11장 당뇨병성 족궤양 시장 : 아시아태평양 국가별 분석

• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양

제12장 아시아태평양의 당뇨병성 족궤양 시장 업계 상황

• 아시아태평양의 당뇨병성 족궤양 시장 성장 전략
• 무기적 성장 전략
• 유기적 성장 전략

제13장 아시아태평양의 당뇨병성 족궤양 시장 - 주요 기업 개요

• Convatec Group Plc
• 3M Co
• Coloplast AS
• Smith & Nephew Plc
• B. Braun SE
• Molnlycke Health Care AB
• MiMedx Group Inc
• URGO MEDICAL Australia Pty Ltd
• Medline Industries LP
• Organogenesis Inc.

제14장 부록

LSH

영문 목차

영문목차

The Asia Pacific diabetic foot ulcer market was valued at US$ 1,455.82 million in 2022 and is expected to reach US$ 2,472.61 million by 2030; it is estimated to grow at a CAGR of 6.8% from 2022 to 2030.

Surge In Geriatric Population Fuels the Asia Pacific Diabetic Foot Ulcer Market.

Age-associated diabetes is common globally. The deficiency of insulin secretion develops with age and the insulin resistance increases due to a change in body composition and sarcopenia. According to Endocrine Society, an estimated 33% of adults aged 65 or older have diabetes. Additionally, the population is more at risk of developing diabetes-related complications. According to the Global Ageing Survey 2019, the pace of aging (i.e., people aged 60 and above) by 2050 will be nearly a quarter or more in most regions across the world. Older adults are more likely to be diabetic and are further anticipated to develop diabetic foot ulcers and chronic wounds that can severely impact the quality of life. Therefore, with the growing aging population, the demand for advanced diabetic foot ulcer treatments will continue to increase in the coming years.

Asia Pacific Diabetic Foot Ulcer Market Overview

Diabetic foot disease is one of the leading causes of amputation among the population of Asia Pacific. Diabetic foot disease is Australia's leading cause of amputation and is among the top 20 causes of hospital admissions. As per Diabetic Feet Australia, in 2023, it has been estimated that nearly 300,000 Australians are at risk of developing diabetic foot disease, and 50,000 people live with it. Similarly, according to a study published in 2023 in Wiley Online Library, diabetic foot disease in China is as high as 30% among the diabetic population. Thus, the prevalence of diabetic foot disease in the region will drive the market growth in the upcoming years.

Market players in Asia Pacific are actively developing treatment options for diabetic foot ulcers. For instance, Cannenta, an Australia-based biotechnology company, is engaged in the development of advance wound care therapies for diabetic foot ulcers. In March 2021, Cynata Therapeutics Limited, an Australian clinical-stage stem cell and regenerative medicine company, collaborated with TekCyte Pty Ltd. for the commercial development of Cynata's mesenchymal stem cells product for diabetic foot ulcers. Therefore, the increasing prevalence of diabetes, rising cases of diabetic foot disease, and initiatives by market players are expected to boost the market growth in Asia Pacific.

Asia Pacific Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Diabetic Foot Ulcer Market Segmentation

Based on treatment type, the Asia Pacific diabetic foot ulcer market is segmented into advanced wound care dressings, therapy device, and biologics. The advanced wound care dressings segment held a larger share in 2022.

Based on ulcer type, the Asia Pacific diabetic foot ulcer market is segmented into neuro-lschemic ulcers, neuropathic ulcers, and ischemic ulcers. The neuro-lschemic ulcers segment held a larger share in 2022.

Based on infection severity, the Asia Pacific diabetic foot ulcer market is segmented into mild, moderate, and severe. The mild segment held a larger share in 2022.

Based on end user, the Asia Pacific diabetic foot ulcer market is segmented into hospitals, ambulatory surgical centers, and home care. The hospitals segment held a larger share in 2022.

Based on country, the Asia Pacific diabetic foot ulcer market is segmented into China, South Korea, Japan, Australia, India, and the Rest of Asia Pacific. China dominated the Asia Pacific diabetic foot ulcer market in 2022.

Convatec Group Plc, 3M Co, Coloplast AS, Smith & Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc., Molnlycke Health Care AB, MiMedx Group Inc, and URGO Medical Australia Pty Ltd are some of the leading companies operating in the Asia Pacific diabetic foot ulcer market.

Table Of Contents

Table of Content

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Asia Pacific Diabetic Foot Ulcer Market Landscape

• 4.1 Overview

5. Asia Pacific Diabetic Foot Ulcer Market - Key Industry Dynamics

• 5.1 Market Drivers:
  • 5.1.1 High Prevalence of Diabetes and Related Chronic Wounds
  • 5.1.2 Surge in Geriatric Population
• 5.2 Market Restraints
  • 5.2.1 High Cost of Advanced Wound Care Treatments
• 5.3 Market Opportunities
  • 5.3.1 Growing Research Activities to Unveil Novel Wound Treatment Products
• 5.4 Future Trends
  • 5.4.1 Use of 3D Printing in Wound Care Management
• 5.5 Impact Analysis:

6. Diabetic Foot Ulcer Market - Asia Pacific Market Analysis

• 6.1 Asia Pacific Diabetic Foot Ulcer Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - by Treatment Type

• 7.1 Overview
• 7.2 Asia Pacific Diabetic Foot Ulcer Market Revenue Share, by Treatment Type 2022 & 2030 (%)
• 7.3 Advanced Wound Care Dressings
  • 7.3.1 Overview
  • 7.3.2 Advanced Wound Care Dressings: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.3 Alginate Dressings
    • 7.3.3.1 Overview
    • 7.3.3.2 Alginate Dressings: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.4 Hydrofiber Dressings
    • 7.3.4.1 Overview
    • 7.3.4.2 Hydrofiber Dressings: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.5 Foam Dressings
    • 7.3.5.1 Overview
    • 7.3.5.2 Foam Dressings: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.6 Collagen Dressing
    • 7.3.6.1 Overview
    • 7.3.6.2 Collagen Dressing: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.7 Film Dressing
    • 7.3.7.1 Overview
    • 7.3.7.2 Film Dressing: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3.8 Other Dressings
    • 7.3.8.1 Overview
    • 7.3.8.2 Other Dressing: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Biologics
  • 7.4.1 Overview
  • 7.4.2 Biologics: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4.3 Growth Factors
    • 7.4.3.1 Overview
    • 7.4.3.2 Growth Factors: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4.4 Skin Graft
    • 7.4.4.1 Overview
    • 7.4.4.2 Skin Graft: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Therapy Device
  • 7.5.1 Overview
  • 7.5.2 Therapy Device: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5.3 Negative Pressure Wound Therapy
    • 7.5.3.1 Overview
    • 7.5.3.2 Negative Pressure Wound Therapy: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5.4 Ultrasound Therapy
    • 7.5.4.1 Overview
    • 7.5.4.2 Ultrasound Therapy: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Ulcer Type

• 8.1 Overview
• 8.2 Asia Pacific Diabetic Foot Ulcer Market Revenue Share, By Ulcer Type 2022 & 2030 (%)
• 8.3 Neuropathic Ulcers
  • 8.3.1 Overview
  • 8.3.2 Neuropathic Ulcers: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Ischemic Ulcers
  • 8.4.1 Overview
  • 8.4.2 Ischemic Ulcers: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Neuro-ischemic Ulcers
  • 8.5.1 Overview
  • 8.5.2 Neuro-ischemic Ulcers: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Infection Severity

• 9.1 Overview
• 9.2 Asia Pacific Diabetic Foot Ulcer Market Revenue Share, By Infection Severity 2022 & 2030 (%)
• 9.3 Mild, Moderate, and Severe
  • 9.3.1 Overview
  • 9.3.2 Mild: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3.3 Moderate: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3.4 Severe: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By End User

• 10.1 Overview
• 10.2 Asia Pacific Diabetic Foot Ulcer Market Revenue Share, By End User 2022 & 2030 (%)
• 10.3 Hospitals
  • 10.3.1 Overview
  • 10.3.2 Hospitals: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 10.4 Ambulatory Surgical Centers
  • 10.4.1 Overview
  • 10.4.2 Ambulatory Surgical Centers: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)
• 10.5 Home Care
  • 10.5.1 Overview
  • 10.5.2 Home Care: Asia Pacific Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US$ Million)

11. Diabetic Foot Ulcer Market - Asia Pacific Country Analysis

• 11.1 Asia Pacific Diabetic Foot Ulcer Market, Revenue and Forecast to 2030
  • 11.1.1 Overview
    • 11.1.1.1 Asia Pacific Diabetic Foot Ulcer Market by Country
    • 11.1.1.2 China
      • 11.1.1.2.1 China Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.2.2 China Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.2.3 China Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.2.3.1 China: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.2.3.2 China: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.2.3.3 China: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.2.4 China Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.2.5 China Diabetic Foot Ulcer Market, by End User
    • 11.1.1.3 Japan
      • 11.1.1.3.1 Japan Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.3.2 Japan Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.3.3 Japan Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.3.3.1 Japan: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.3.3.2 Japan: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.3.3.3 Japan: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.3.4 Japan Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.3.5 Japan Diabetic Foot Ulcer Market, by End User
    • 11.1.1.4 India
      • 11.1.1.4.1 India Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.4.2 India Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.4.3 India Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.4.3.1 India: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.4.3.2 India: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.4.3.3 India: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.4.4 India Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.4.5 India Diabetic Foot Ulcer Market, by End User
    • 11.1.1.5 Australia
      • 11.1.1.5.1 Australia Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.5.2 Australia Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.5.3 Australia Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.5.3.1 Australia: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.5.3.2 Australia: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.5.3.3 Australia: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.5.4 Australia Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.5.5 Australia Diabetic Foot Ulcer Market, by End User
    • 11.1.1.6 South Korea
      • 11.1.1.6.1 South Korea Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.6.2 South Korea Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.6.3 South Korea Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.6.3.1 South Korea: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.6.3.2 South Korea: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.6.3.3 South Korea: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.6.4 South Korea Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.6.5 South Korea Diabetic Foot Ulcer Market, by End User
    • 11.1.1.7 Rest of Asia Pacific
      • 11.1.1.7.1 Rest of Asia Pacific Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.1.7.2 Rest of Asia Pacific Diabetic Foot Ulcer Market, by Ulcer Type
      • 11.1.1.7.3 Rest of Asia Pacific Diabetic Foot Ulcer Market, by Treatment Type
      • 11.1.1.7.3.1 Rest of Asia Pacific: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
      • 11.1.1.7.3.2 Rest of Asia Pacific: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
      • 11.1.1.7.3.3 Rest of Asia Pacific: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
      • 11.1.1.7.4 Rest of Asia Pacific Diabetic Foot Ulcer Market, by Infection Severity
      • 11.1.1.7.5 Rest of Asia Pacific Diabetic Foot Ulcer Market, by End User

12. Asia Pacific Diabetic Foot Ulcer Market Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in the Asia Pacific Diabetic Foot Ulcer Market
• 12.3 Inorganic Growth Strategies
  • 12.3.1 Overview
• 12.4 Organic Growth Strategies
  • 12.4.1 Overview

13. Asia Pacific Diabetic Foot Ulcer Market - Key Company Profiles

• 13.1 Convatec Group Plc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 3M Co
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Coloplast AS
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 Smith & Nephew Plc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 B. Braun SE
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 Molnlycke Health Care AB
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 MiMedx Group Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 URGO MEDICAL Australia Pty Ltd
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
• 13.9 Medline Industries LP
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
• 13.10 Organogenesis Inc.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

• 14.1 About Us
• 14.2 Glossary of Terms

관련자료